Novel monoclonal antibody can substantially lower triglycerides in patients with acute pancreatitis

The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai. The fully human monoclonal antibody produced sustained reductions in triglyceride levels of up to 82 percent, depending on the patient’s genotype, while also lowering the…

Multimodal therapy may hold key to treating aggressive childhood cancer

Research led by scientists at Children’s Cancer Institute and published this week in the international journal, Clinical Cancer Research, has found a combination of therapies that appears to be highly effective against high-risk neuroblastoma and other forms of aggressive childhood cancer. Up to half of all cases of neuroblastoma newly diagnosed in children are ‘high-risk’,…

Tailored, earlier heart failure rehab has physical, emotional benefits for patients

An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehabilitation programs. Supported by the National Institute on Aging (NIA), part of the National institutes of Health, these new study results were published May 16 in the…